Sofia® SARS Antigen FIA
Sofia® Analyzers
Sofia® SARS Antigen FIA

For use with Sofia 2 and Sofia 

FDA Emergency Use Authorization

The Sofia SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia SARS Antigen FIA, with the Sofia 2 and Sofia analyzers, provides automated and objective results in 15 minutes, allowing for COVID-19 testing of symptomatic patients within the first five days of symptoms and asymptomatic patients when tested serially.

Healthcare professionals can purchase the Sofia SARS Antigen FIA through select authorized distributors.

Test kit (US, Nasal swab) 
Catalog number: 20374 
Kit size/Case size: 25/12

Test kit (XUS) 
Catalog number: 20378 
Kit size/Case size: 25/12

Where can I go for updates and more information?

CDC: 
General Information - Coronavirus (COVID-19) 
Laboratory Biosafety

FDA: 
General Information - Coronavirus (COVID-19) 
Emergency Use Authorizations 
Additional Information - QuidelOrtho's EUA COVID-19 Products (Scroll down to the list of EUA products and enter “QuidelOrtho” in the search box)

The Sofia® SARS Antigen FIA has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

Contact us

Sofia® Analyzers
Sofia® SARS Antigen FIA
Sofia® SARS Antigen FIA

For use with Sofia 2 and Sofia 

FDA Emergency Use Authorization

The Sofia SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia SARS Antigen FIA, with the Sofia 2 and Sofia analyzers, provides automated and objective results in 15 minutes, allowing for COVID-19 testing of symptomatic patients within the first five days of symptoms and asymptomatic patients when tested serially.

Healthcare professionals can purchase the Sofia SARS Antigen FIA through select authorized distributors.

Test kit (US, Nasal swab) 
Catalog number: 20374 
Kit size/Case size: 25/12

Test kit (XUS) 
Catalog number: 20378 
Kit size/Case size: 25/12

Where can I go for updates and more information?

CDC: 
General Information - Coronavirus (COVID-19) 
Laboratory Biosafety

FDA: 
General Information - Coronavirus (COVID-19) 
Emergency Use Authorizations 
Additional Information - QuidelOrtho's EUA COVID-19 Products (Scroll down to the list of EUA products and enter “QuidelOrtho” in the search box)

The Sofia® SARS Antigen FIA has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless authorization is terminated or revoked sooner.

Contact us

Features & benefits

Rapid results in 15 minutes to support efficient dispositioning of patients.

Dual work modes adjust to your volume fluctuations. Allows for significant throughput and batching of samples in READ NOW Mode.

All necessary components included in kit are ready for use with Sofia 2 and Sofia for nasal swab procedure.

Find what you need

To access safety data sheets, package inserts, quick reference guides and all other technical and promotional materials, visit our technical documents library.

 

Technical documentation

Product specifications
Time to results 15 minutes
Sample type Direct nasal swabs
Kit storage conditions Room temperature (15°C to 35°C / 59°F to 86°F)
Controls Positive and negative, included in kit
PPA 96.7%
NPA 100% 
CLIA complexity Waived*

Sofia SARS Antigen FIA training video

s-card-img

Sofia SARS Antigen FIA batch testing protocol

s-card-img

Related products

Lyra® Direct SARS-CoV-2 Assay

Lyra® SARS-CoV-2 Assay

Savanna® Respiratory Viral Panel-4

Solana® SARS-CoV-2 Assay

QuickVue® SARS Antigen Test

Sofia® 2 Flu + SARS Antigen FIA

Virena® System

COVID-19